Fate Therapeutics (FRA:F6T) 3-Year EBITDA Growth Rate : -4.90% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics 3-Year EBITDA Growth Rate?

Fate Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.42.

During the past 3 years, the average EBITDA Per Share Growth Rate was -4.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -15.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fate Therapeutics was 33.50% per year. The lowest was -30.10% per year. And the median was -3.50% per year.

Competitive Comparison of Fate Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Fate Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fate Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's 3-Year EBITDA Growth Rate falls into.

Fate Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Fate Therapeutics (FRA:F6T) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Fate Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Fate Therapeutics (FRA:F6T) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (FRA:F6T) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

FATE:USA F6T:Germany

Address

12278 Scripps Summit Drive, San Diego, CA, USA, 92131

Website

https://www.fatetherapeutics.com

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Fate Therapeutics (FRA:F6T) Headlines

No Headlines